This clinical trial is focused on studying Primary Progressive Multiple Sclerosis (PPMS), a type of multiple sclerosis that gradually worsens over time. The study is testing a new treatment called Tolebrutinib, which is a medication taken as a film-coated tablet. Tolebrutinib is being compared to a placebo to see if it can help delay the progression of disability in people with PPMS.
The purpose of the study is to determine how effective Tolebrutinib is in slowing down the progression of disability in individuals with PPMS. Participants in the study will be randomly assigned to receive either Tolebrutinib or a placebo. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo. This helps ensure that the results are unbiased and reliable.
Throughout the study, participants will be monitored for changes in their condition, including any progression of disability. The study will also look at other factors such as changes in brain volume, cognitive function, and overall quality of life. Safety and tolerability of the medication will be closely observed to ensure the well-being of all participants. The study aims to provide valuable information on whether Tolebrutinib can be a beneficial treatment option for those living with PPMS.
1joining the study
Upon joining the study, the participant will be randomly assigned to receive either the study medication, tolebrutinib, or a placebo. This process is double-blind, meaning neither the participant nor the study team will know which treatment is being administered.
2medication administration
The participant will take the assigned medication orally in the form of a film-coated tablet. The specific dosage and frequency will be determined by the study protocol and communicated to the participant at the start of the trial.
3monitoring and assessments
Throughout the study, the participant will undergo regular assessments to monitor the progression of primary progressive multiple sclerosis (PPMS). These assessments will include evaluations of disability progression, brain imaging, and cognitive function tests.
The primary goal is to determine if the medication delays disability progression compared to the placebo.
4safety and tolerability checks
The participant’s safety and the tolerability of the medication will be closely monitored. This includes regular check-ups and reporting any side effects experienced during the trial.
5end of study
The study is estimated to conclude by June 28, 2025. At the end of the study, the participant will undergo final assessments to evaluate the overall impact of the treatment on their condition.
Who Can Join the Study?
Must be between 18 to 55 years old.
Must have a diagnosis of Primary Progressive Multiple Sclerosis (PPMS) according to specific guidelines from 2017.
Must have a score between 2.0 to 6.5 on the Expanded Disability Status Scale (EDSS), which is a way to measure disability in people with multiple sclerosis.
Must have positive cerebrospinal fluid oligoclonal bands or an elevated Immunoglobulin G (IgG) index. These are tests that help confirm the diagnosis of multiple sclerosis.
Must use birth control methods that follow local rules for people in clinical studies.
Must not be pregnant or breastfeeding. If a woman can have children, she must agree to use an acceptable method of birth control.
Must not have access to a medication called ocrelizumab, or if they do, they must not tolerate it due to side effects or safety reasons, or it must not work effectively for them.
SAR442168 is a medication being studied for its potential to slow down the progression of disability in people with Primary Progressive Multiple Sclerosis (PPMS). This medication is being compared to a placebo to evaluate its effectiveness and safety in managing the symptoms and progression of this condition.
Primary Progressive Multiple Sclerosis – This is a form of multiple sclerosis characterized by a gradual worsening of neurological function from the onset of symptoms, without early relapses or remissions. It primarily affects the spinal cord and brain, leading to increasing disability over time. Symptoms may include problems with walking, muscle stiffness, and weakness. Unlike other forms of multiple sclerosis, this type does not have periods of remission, making the progression more continuous. The disease can also affect cognitive functions, leading to difficulties with memory and thinking. Changes in brain volume and the presence of lesions can be observed through imaging techniques like MRI.
The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Austria 
Belgium 
Bulgaria 
Croatia 
Czechia 
Denmark 
Estonia 
France 
Germany 
Greece 
Hungary 
Italy 
Norway 
Poland 
Portugal 
Romania 
Spain 
Sweden 
The Netherlands